Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Harrow Inc
(NQ:
HROW
)
16.76
+0.60 (+3.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harrow Inc
< Previous
1
2
3
4
Next >
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
January 05, 2023
From
Harrow Health, Inc.
Via
Business Wire
Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
December 21, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Secures Capital to Close Recently Announced Acquisition
December 16, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones
December 14, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Prices $25 Million Offering
December 14, 2022
From
Harrow
Via
Business Wire
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
December 14, 2022
From
Harrow
Via
Business Wire
Harrow and iOR Partners Expand National Product Supply Agreement
November 30, 2022
From
Harrow
Via
Business Wire
Harrow Announces Third Quarter 2022 Financial Results
November 14, 2022
From
Harrow
Via
Business Wire
Harrow Launches Atropine.com
November 10, 2022
From
Harrow
Via
Business Wire
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
October 28, 2022
From
Harrow
Via
Business Wire
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
October 27, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Sells Non-Ophthalmic Compounding Business
October 05, 2022
From
Harrow
Via
Business Wire
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
September 29, 2022
From
Harrow
Via
Business Wire
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
September 27, 2022
From
Harrow
Via
Business Wire
Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 11, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Announces Second Quarter 2022 Financial Results
August 09, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
June 24, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Announces First Quarter 2022 Financial Results
May 05, 2022
From
Harrow Health, Inc.
Via
Business Wire
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
May 04, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
April 22, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
April 20, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Announces Appointments to Its Board of Directors
March 31, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
February 24, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
February 22, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health to Present at Aegis Virtual Conference
February 15, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Publishes Corporate Transparency Report
February 08, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health to Participate in H.C. Wainwright BioConnect Conference
January 10, 2022
From
Harrow Health, Inc.
Via
Business Wire
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
January 04, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
December 20, 2021
From
Harrow Health, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.